Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis

At clinically relevant ixazomib concentrations, in vitro studies demonstrated that no specific cytochrome P450 (CYP) enzyme predominantly contributes to ixazomib metabolism. However, at higher than clinical concentrations, ixazomib was metabolized by multiple CYP isoforms, with the estimated relativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Neeraj, Hanley, Michael J., Venkatakrishnan, Karthik, Bessudo, Alberto, Rasco, Drew W., Sharma, Sunil, O'Neil, Bert H., Wang, Bingxia, Liu, Guohui, Ke, Alice, Patel, Chirag, Rowland Yeo, Karen, Xia, Cindy, Zhang, Xiaoquan, Esseltine, Dixie‐Lee, Nemunaitis, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Drug Interactions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811830/
https://www.ncbi.nlm.nih.gov/pubmed/28800141
http://dx.doi.org/10.1002/jcph.988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811830/
https://www.ncbi.nlm.nih.gov/pubmed/28800141
http://dx.doi.org/10.1002/jcph.988

Ejemplares similares